Results 161 to 170 of about 7,117 (221)

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood
Background With the advent of effective targeted therapy, there is growing interest in chemotherapy-free regimens in patients (pts) with mantle cell lymphoma (MCL). Triplet combinations of the BTK inhibitors ibrutinib or zanubrutinib, venetoclax (V)
A. Kim, Peter A Riedell, C. Ryan, R. Redd, Clare Phinney, Juniper Mai, S. Pazienza, Caitlin Bravo, V. Kats, Salah Abdulkarim, Susan M Waisgerber, R. Merryman, David C. Fisher, Inhye E. Ahn, J. Crombie, O. Odejide, Ann S. LaCasce, C. Jacobson, Eric Jacobsen, E. Parry, D. Qualls, A. Bessnow, M. Davids, Jennifer R. Brown, Jon Arnason, Michael Leukam, P. Armand, J. Kline, M. Murakami   +28 more
semanticscholar   +1 more source

A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo

Cancers
Simple Summary Although oral targeted therapies have improved the treatment of mantle cell lymphoma (MCL), outcomes remain poor. We recently showed that an oral form of Bendamustine works as well as the intravenous version.
Dimitrios Filioglou, Nina Santa-Cruz, Geovana S F Leite, Dan W Davini, Megan J. Cracchiolo, Forrest L Baker, Muhammad Husnain, Richard J. Simpson, Vasilios Voudouris, Emmanuel Katsanis   +9 more
semanticscholar   +1 more source

mPEG-PCL Nanoparticles to Improve Oral Bioavailability of Acalabrutinib: Effect of Polymer Lipophilicity and Hydrophilicity on Physicochemical Properties and In Vivo Performance in Rats

Pharmaceutics
Background/Objectives: This research focuses on the development and optimization of polymer–lipid hybrid nanoparticles (PLHNs) using two grades of mPEG-PCL co-polymers in combination with DPPC and lecithin to address the biopharmaceutical challenges of ...
Swagata Sinha, P. Ravi, S. R. Rashmi, Łukasz Szeleszczuk   +3 more
semanticscholar   +1 more source

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Blood
Background Continuous therapy with covalent BTK inhibitors (BTKi) has become a cornerstone strategy for patients with chronic lymphocytic leukemia (CLL).
R. Guièze, E. Ferrant, F. Merabet, Lysiane Molina, D. Chaoui, P. Feugier, T. Aurran-Schleinitz, S. Chebrek, Hugo Gonzalez, A. Clavert, M. Ochmann, K. Laribi, A. Michallet, Vincent Lévy, B. Hivert, C. Dartigeas, Laurence Simon, Damien Roos Weil, A. Quinquenel, Anne-Violaine Doncker, J. Gay, Antoine Bonnet, M. Dilhuydy, E. Tchernonog, Bernard Drénou, Sophie de Guibert, L. Sanhes, S. Leprêtre, O. Tournilhac, F. Nguyen‐Khac, V. Rouillé, Marie Poinsignon, Cabarrou Bastien, Loïc Ysebaert   +33 more
semanticscholar   +1 more source

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Journal of Clinical Oncology
PURPOSE The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type TP53; however, due ...
M. Davids, C. Ryan, B. Lampson, Yue Ren, S. Tyekucheva, Stacey M. Fernandes, J. Crombie, A. Kim, Matthew Weinstock, J. Montegaard, H. Walker, Claire Greenman, V. Patterson, C. Jacobson, A. LaCasce, Philipe Armand, David C. Fisher, Steve Lo, Adam J. Olszewski, J. Arnason, Inhye E. Ahn, Jennifer R. Brown   +21 more
semanticscholar   +1 more source

Initial treatment of chronic lymphocytic leukemia with low-dose high-frequency rituximab followed by addition of acalabrutinib

Blood
Introduction: Rituximab is effective at removing circulating CLL cells by inducing antibody-dependent cellular phagocytosis (ADCP). This ADCP could be limited by low CLL cell CD20 levels (innate or acquired), intrinsic CLL cell resistance to ADCP ...
Charles Chu, Clare B. Heffernan, Nydia Jaimes-Delgadillo, C. Herne, Jennifer E. Bruno, Andrea Baran, Paul M. Barr, Ronald P Taylor, John M. Ashton, Michael Elliott, Clive Zent   +10 more
semanticscholar   +1 more source

Acalabrutinib: First Global Approval

Drugs, 2017
Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and ...
Anthony, Markham, Sohita, Dhillon
openaire   +2 more sources

Differential cardiotoxicity of acalabrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: A retrospective cohort study from 2000-2025 using TriNetX database.

Journal of Clinical Oncology
e19022 Background: Chronic lymphocytic leukemia (CLL) is a common adult leukemia that originates by dysfunctional development of the lymphocytes.
Abdul Qadeer, Raza Aslam, Allahdad Khan, Prishavi Kansal, Pavisankar Biju Seena, Ahmed Sajid, Manahil Ahmed, Shree Rath, Aoun Zaib Khan, Mahnoor Javaid, Samer Jumean, Robert W. Kirchoff   +11 more
semanticscholar   +1 more source

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood
BACKGROUND Covalent Bruton's tyrosine kinase inhibitors (cBTKi) have revolutionized the treatment of Chronic Lymphocytic Leukemia (CLL), improving outcomes above all in patients with a poor prognosis.
L. Laurenti, A. Mosca, Feliciana Guglielmi, A. Tomasso, A. Visentin, L. Scarfò, R. Murru, M. Gentile, A. Galitzia, E. Cappello, F. Autore, L. Stirparo, Tommaso Quaranta, M. C. Montalbano, Francesca Martini, Massimo Moratti, Giuliana Farina, Vanessa Innao, G. Catania, S. Bellesi, Caterina Chessa, R. Pasquale, C. Vitale, M. Coscia, R. Moia, Alessandro Sanna, Francesco Malaspina, Isacco Ferrarini, M. Varettoni, V. Gattei, P. Ghia, Diana Giannarelli, I. Innocenti   +32 more
semanticscholar   +1 more source

Risk of second primary malignancies in patients with chronic lymphocytic leukemia treated with zanubrutinib and acalabrutinib: A real-world data analysis

Blood
Background: Second primary malignancies (SPMs) are one of the complications in patients with chronic lymphocytic leukemia (CLL). Zanubrutinib and acalabrutinib, as newer generation of Bruton tyrosine kinase inhibitors (BTKi), have been developed ...
Lay She Ng, Yone Phar Lin, Ashtyn Phillippi, Martin Cuevas, Glennis Cho, W. Ng, Oksana Karpov, Utpal Dave   +7 more
semanticscholar   +1 more source